News for Atara Biotherapeutics, Inc. (ATRA)

On May 16, 2025, Redmile Group, LLC (Trades, Portfolio) executed a notable transaction involving Atara Biotherapeutics Inc. The firm added 263,506 shares of Ata

Atara Biotherapeutics (ATRA) has expanded its Board of Directors by appointing James Huang and Nachi Subramanian. This development follows the successful conclu

Atara Biotherapeutics (ATRA) adds James Huang and Nachi Subramanian to its Board of Directors. The appointments follow Atara's recent $16 million offeri

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to devel

Key Highlights: Atara Biotherapeutics announces a new share offering set to raise $16 million. Analysts forecast a potential upside of 131.97% from the c

[url="]Atara Biotherapeutics, Inc.[/url] (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell plat

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to devel

Atara Biotherapeutics, Inc. (ATRA) announces a $16 million offering of common stock and pre-funded warrants. The offering consists of 834,237 shares at

[url="]Atara Biotherapeutics, Inc.[/url] (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell plat

Atara Biotherapeutics (ATRA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 68.85% and 150.02%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

[url="]Atara Biotherapeutics, Inc.[/url] (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell plat

The consensus price target hints at a 33% upside potential for Atara Biotherapeutics (ATRA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

[url="]Atara Biotherapeutics, Inc.[/url] (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell plat

Atara Biotherapeutics (ATRA) plans to cut around 50% of its workforce, just a little over a week after the FDA declined to approve its immunotherapy Ebvallo. Read more here.

[url="]The Schall Law Firm[/url], a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Biot

Atara Biotherapeutics (ATRA) stock slips as company faces an FDA clinical hold after rejection of lead candidate Ebvallo. Read more here.

[url="]Atara Biotherapeutics, Inc.[/url] (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell plat

Atara Biotherapeutics has just announced a CRL by FDA for EBVALLO. Click here to read more about ATRA stock and why it is rated as a Buy.